116 related articles for article (PubMed ID: 21852299)
1. Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis.
Hoes JN; Van der Goes MC; Jacobs JW; Lafeber FP; Bijlsma JW; Van Roon JA
Rheumatology (Oxford); 2011 Oct; 50(10):1921-4. PubMed ID: 21852299
[TBL] [Abstract][Full Text] [Related]
2. Effects of alendronate or alfacalcidol on bone metabolic indices and bone mineral density in patients with ophthalmologic disease treated with glucocorticoid.
Ikeda T; Maruyama K; Kaji H; Akagi M
Mod Rheumatol; 2014 Jul; 24(4):671-6. PubMed ID: 24313921
[TBL] [Abstract][Full Text] [Related]
3. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
4. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
5. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol.
Takeda S; Kaneoka H; Saito T
Mod Rheumatol; 2008; 18(3):271-6. PubMed ID: 18427724
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty.
Iwamoto N; Inaba Y; Kobayashi N; Ishida T; Yukizawa Y; Saito T
J Bone Joint Surg Am; 2011 Jul; 93(13):1203-9. PubMed ID: 21776573
[TBL] [Abstract][Full Text] [Related]
8. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
9. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
10. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Lv F; Guan Y; Ma D; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
Clin Endocrinol (Oxf); 2018 Mar; 88(3):380-387. PubMed ID: 29266368
[TBL] [Abstract][Full Text] [Related]
12. Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study.
Kaji H; Kuroki Y; Murakawa Y; Funakawa I; Funasaka Y; Kanda F; Sugimoto T
Osteoporos Int; 2010 Sep; 21(9):1565-71. PubMed ID: 19921083
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
14. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
15. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol.
Trabulus S; Altiparmak MR; Apaydin S; Serdengecti K; Sariyar M
Transplant Proc; 2008; 40(1):160-6. PubMed ID: 18261575
[TBL] [Abstract][Full Text] [Related]
16. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
Park JH; Park KH; Cho S; Choi YS; Seo SK; Lee BS; Park HS
Menopause; 2013 Jul; 20(7):747-53. PubMed ID: 23511701
[TBL] [Abstract][Full Text] [Related]
17. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
19. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
20. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
Book C; Karlsson M; Akesson K; Jacobsson L
Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]